Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
14.06
-0.31 (-2.16%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Contineum Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
51
Market Cap
525.65M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 50.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Arvinas | 89.40M |
| 4D Molecular Therapeutics | 88.24M |
| Assembly Biosciences | 71.10M |
| Verastem | 49.59M |
| Adlai Nortye | 5.00M |
| Prime Medicine | 4.03M |
| SL Science Holding | 3.36M |
| Silence Therapeutics | 839.00K |
CTNM News
- 25 days ago - Contineum publishes manuscript on PIPE-791 in Journal of Medicinal Chemistry - TheFly
- 25 days ago - Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry - Business Wire
- 6 weeks ago - Contineum Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference - Business Wire
- 2 months ago - Contineum Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Contineum price target raised to $16 from $14 at Morgan Stanley - TheFly
- 2 months ago - Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference - Business Wire